News

BioNTech SE is currently sponsoring a Phase II clinical study titled A Phase II, Multisite, Open-label, Single Arm Trial of BNT327 in Combination With Docetaxel in Second-line Stage IV Non-small Cell ...
Released Tuesday, the AAP's recommendations call for routine vaccination of children ages 6 months to 2 years, citing ...
Multiple scientists and doctors have spoken out against this decision, including infectious diseases expert Dr. Thomas A. Russo, who told Newsweek that mRNA vaccines "will be critical when the next, ...
Texas school districts are coming back from summer with a rising number of parents asking for vaccine exemption forms and a ...
Pfizer's Canadian unit and BioNTech said they have received approval in Canada for their updated Comirnaty Covid-19 vaccine. The companies said Monday the updated vaccine targets the Omicron LP.8.1 ...
COVID-19 activity is rising in much of the country. Data shows overall respiratory virus spread is very low in the U.S. But ...
The Food and Drug Administration could pull Pfizer's coronavirus vaccine emergency authorization for children under age 5.
Discover how melanoma vaccines are gaining traction in the clinic and could soon become a treatment option for this deadly ...
GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...
Pfizer (PFE) stock and BioNTech (BNTX) stock in focus as FDA may not renew the authorization for their pediatric COVID shot. Read more here.
MAINZ, Germany, August 4, 2025-- BioNTech SE today reported financial results for the six months ended June 30, 2025 and provided an update on its corporate progress. "In the second quarter, we ...
BioNTech SE is a biotechnology company that focuses on developing and manufacturing mRNA-based vaccines and therapeutics. It is known for its COVID-19 vaccine developed in partnership with Pfizer ...